PD1 Resistant Head and Neck Cancer Market Current and Future Projection 2023 to 2033
The global PD1 resistant head & neck cancer market is predicted to be worth US$ 1.54 billion in 2023 and US$ 5 billion by 2033, with a CAGR of 12.5%. The growing geriatric population, as well as the increasing number of initiatives by government and non-governmental organisations such as Support for People with Oral and PD1 Resistant Head and Neck Cancer (SPOHNC), are creating a highly favourable environment for the global PD1 resistant head and neck cancer market to grow. Immunotherapy is an innovative treatment for cancer, including head and neck, lymphoma, melanoma, and non-small cell lung cancer. Some tumors respond well to traditional therapies such as chemotherapy. In other instances, immunotherapy is combined with conventional cancer therapies to increase the body’s natural defenses against cancer. As part of its regular functionality, the immune system discovers and eliminates aberrant cells, so preventing or stifling the formation of several malignancies. Immune cells, fo...